Strata Critical Medical SRTA
- Market cap
- $412.3M
- PE
- n/m
- not a meaningful number
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 1.6×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $256M
- +49% on a year ago
- Net margin
- 15.7%
- Free cash flow yield
- −11.7%
Strata Critical Medical trades at 1.6× sales. Revenue was $256M over the last twelve months, up 49% on a year earlier with a 16% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $71.4M+56% | $47.5M+25% | $51.5M+14% | $67.9M+11% | $36.1M−50% | $54.4M+15% | $35.9M−30% | $45.1M−34% | $49.3M+37% | $66.8M+23% | $67.4M+87% | $72.5M+61% | |
| Cost of revenue | $55.9M+53% | $38.5M+16% | $41.4M+9% | $51.6M+2% | $28.6M−49% | $41.8M+9% | $28.9M−30% | $36.1M−30% | $37.7M+32% | $55.1M+32% | $53.3M+84% | $57.3M+59% |
| Gross profit | $15.6M+68% | $9M+81% | $10.1M+42% | $16.4M+58% | $7.5M−52% | $12.6M+40% | $7.1M−30% | $9M−45% | $11.6M+55% | $11.7M−7% | $14.1M+100% | $15.2M+69% |
| R&D | $1.1M−47% | $988K−39% | $670K−40% | $971K−33% | $417K−61% | $743K−25% | $812K+21% | $915K−6% | $453K+9% | n/a | n/a | n/a |
| SG&A | $22M+24% | $43.7M+90% | $19.3M+3% | $27.5M+30% | $14.2M−35% | $20.2M−54% | $12.3M−36% | $13.3M−52% | $16.8M+18% | $16.8M−17% | $15.6M+27% | $14M+5% |
| −$7.4M−29% | −$35.6M+81% | −$9.9M−23% | −$12.1M−1% | −$7.1M−5% | −$8.4M−77% | −$5.7M−42% | −$4.6M−62% | −$5.6M−21% | −$6.4M−24% | −$3M−48% | −$5.4M+17% | |
| Pre-tax income | $418K | −$35M+115% | −$4.3M−58% | −$11.3M−11% | −$5.6M | −$9.9M−72% | −$1.6M−63% | −$3.4M−70% | −$9.7M+72% | −$5.4M−46% | $2.4M | −$10.5M+209% |
| $129K+130% | −$1M+24% | −$84K−57% | $52K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net income | $289K | −$33.9M+120% | −$4.2M−59% | −$11.3M−7% | −$2M | −$9.8M−71% | −$3.5M−18% | −$3.7M−67% | $57.4M | −$8.8M−10% | $2.2M | −$10.5M+181% |
| $0.00 | −$0.45+105% | −$0.06−57% | −$0.15−12% | −$0.03 | −$0.12−73% | −$0.04−33% | −$0.05−67% | $0.70 | −$0.10−17% | $0.03 | −$0.12+140% | |
| 81M+13% | 74.8M+4% | 75.8M+5% | 77.6M+6% | 78M−4% | 78.5M+5% | 79.9M+5% | 81.3M+5% | 82.5M+6% | 84.7M+8% | 90.2M+13% | 86.2M+6% |
Gross profit: 18 periods, Q4 FY20 to Q3 FY25: not printed by the filing, worked out from its own lines.
EPS, diluted: 5 periods, Q4 FY21 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 4 periods, Q4 FY22 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Care Facilities nearest Strata Critical Medical's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| SRTAStrata Critical Medical | $412.3M | n/m | 10.6× | 1.6× | +49% | 15.7% | |
| VMDViemed Healthcare | $373.3M | 27.2× | 26.1× | 1.2× | +25% | 4.8% | |
| SBCSBC Medical | $543M | 11.2× | 8.2× | 3.1× | −7% | 28.0% | |
| OMDAOmada Health | $1.2B | 316× | 341× | 3.7× | +48% | 1.4% | |
| USPHU S Physical Therapy | $1.3B | 101× | 42.1× | 1.6× | +11% | 4.0% | |
| PNTGPennant | $1.5B | 46.5× | 47.0× | 1.3× | +38% | 2.9% | |
| ARDTArdent Health | $1.7B | 22.3× | 8.5× | 0.3× | +3% | 1.2% | |
| HCSGHealthcare Services | $1.7B | 14.7× | 26.1× | 0.9× | +4% | 6.6% | |
| PGNYProgyny | $2.2B | 31.5× | 55.1× | 1.7× | +6% | 6.0% | |
| ADUSAddus HomeCare | $2.3B | 21.4× | 32.4× | 1.5× | +16% | 7.1% | |
| MDPediatrix Medical | $2.4B | 14.0× | 13.4× | 1.2× | +1% | 9.0% | |
| Peer median | $1.6B | 24.8× | 29.2× | 1.4× | +8% | 5.4% |
Investors who own it
Investors we follow who held Strata Critical Medical at the end of Jun 30, 2026, from their 13F filings.
- Dan LoebThird Point0.6% of portfolio
- Cathie WoodARK Investment Management0.1% of portfoliotrimmed
More on Strata Critical Medical
Each number over time
- PE ratio
- Price to sales ratio
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #2of 42Hospital and care facility stocks with the fastest revenue growth
- #2of 42Hospital and care facility stocks with the highest profit margins
Its groups
About
- Industry
- Medical - Care Facilities
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .